[The role of systemic therapies of non-small cell lung cancer and malignant pleural mesothelioma: updated expert recommendations]

Pneumonol Alergol Pol. 2014;82(2):133-49. doi: 10.5603/PiAP.2014.0019.
[Article in Polish]

Abstract

Lung cancer is the leading cause of cancer related death in Poland. About 85% of all lung cancer constitutes non-small cancer (NSCLC), in which the role of cytotoxic and molecularly targeted drugs is increasing. This article presents the current evidence- based recommendations for the use of these methods in clinical practice in NSCLC and malignant pleural mesothelioma.

Publication types

  • Review

MeSH terms

  • Anaplastic Lymphoma Kinase
  • Angiogenesis Inhibitors / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Carcinoma, Non-Small-Cell Lung / diagnosis
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / surgery
  • Evidence-Based Medicine
  • Humans
  • Immunotherapy / methods
  • Lung Neoplasms / diagnosis
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / surgery
  • Mesothelioma / diagnosis
  • Mesothelioma / drug therapy*
  • Mesothelioma / surgery
  • Mesothelioma, Malignant
  • Molecular Targeted Therapy*
  • Pleural Neoplasms / diagnosis
  • Pleural Neoplasms / drug therapy*
  • Pleural Neoplasms / surgery
  • Poland
  • Postoperative Care
  • Practice Guidelines as Topic*
  • Premedication
  • Receptor Protein-Tyrosine Kinases / antagonists & inhibitors

Substances

  • Angiogenesis Inhibitors
  • Anaplastic Lymphoma Kinase
  • Receptor Protein-Tyrosine Kinases